SRR25617906
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.220
- PANCREAS_BETA_CELLS+0.200
- HEDGEHOG_SIGNALING+0.160
- ESTROGEN_RESPONSE_EARLY+0.120
- SPERMATOGENESIS+0.120
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.110
- MYOGENESIS+0.110
- COAGULATION+0.100
- INTERFERON_ALPHA_RESPONSE+0.100
- APICAL_JUNCTION+0.080
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.440
- PROTEIN_SECRETION-0.380
- MYC_TARGETS_V1-0.370
- G2M_CHECKPOINT-0.360
- OXIDATIVE_PHOSPHORYLATION-0.360
- APOPTOSIS-0.350
- CHOLESTEROL_HOMEOSTASIS-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- ANDROGEN_RESPONSE-0.340
- PI3K_AKT_MTOR_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR4976607 | — | B | 0.892 |
| 2 | BS_4W68NV3M | Med | Medulloblastoma | 0.885 |
| 3 | MNG661 | — | — | 0.877 |
| 4 | MDT-AP-0760 | Med | Medulloblastoma | 0.877 |
| 5 | SRR1797298 | — | cohortSC | 0.876 |
| 6 | ERR4976602 | — | C | 0.874 |
| 7 | MNG771 | — | — | 0.871 |
| 8 | SRR8613808 | — | D | 0.870 |
| 9 | SRR1466850 | GTEX | — | 0.861 |
| 10 | BS_YK6VQ9SJ | DNET | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |